GeneDx Holdings (WGS) Cash & Current Investments (2020 - 2026)

GeneDx Holdings (WGS) has reported Cash & Current Investments for 7 consecutive years, with $170.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 7.24% year-over-year to $170.7 million; the TTM figure through Mar 2026 stood at $170.7 million (up 7.24% YoY), while the FY2025 annual figure was $171.3 million, up 21.32% from the prior year.
• Cash & Current Investments steadied at $170.7 million in Q1 2026 per WGS's latest filing, from $171.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $315.0 million in Q1 2022 and bottomed at $106.9 million in Q2 2024.
• Historically, Cash & Current Investments has averaged $164.6 million across 5 years, with a median of $155.1 million in 2025.
• On a YoY basis, Cash & Current Investments climbed as much as 973.92% in 2022 and fell as far as 69.06% in 2022.
• GeneDx Holdings' Cash & Current Investments stood at $123.9 million in 2022, then grew by 5.01% to $130.1 million in 2023, then advanced by 8.48% to $141.2 million in 2024, then increased by 21.32% to $171.3 million in 2025, then declined by 0.35% to $170.7 million in 2026.
• Business Quant data shows WGS's Cash & Current Investments at $170.7 million in Q1 2026, $171.3 million in Q4 2025, and $155.1 million in Q3 2025.